CN118338912A - Nant covid疫苗交叉反应性 - Google Patents

Nant covid疫苗交叉反应性 Download PDF

Info

Publication number
CN118338912A
CN118338912A CN202280079239.5A CN202280079239A CN118338912A CN 118338912 A CN118338912 A CN 118338912A CN 202280079239 A CN202280079239 A CN 202280079239A CN 118338912 A CN118338912 A CN 118338912A
Authority
CN
China
Prior art keywords
sars
recombinant
protein
seq
etsd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280079239.5A
Other languages
English (en)
Chinese (zh)
Inventor
P·宋-熊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunobiology Co
Original Assignee
Immunobiology Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunobiology Co filed Critical Immunobiology Co
Publication of CN118338912A publication Critical patent/CN118338912A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202280079239.5A 2021-11-30 2022-11-29 Nant covid疫苗交叉反应性 Pending CN118338912A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163284203P 2021-11-30 2021-11-30
US63/284203 2021-11-30
PCT/US2022/080561 WO2023102375A1 (en) 2021-11-30 2022-11-29 Nant covid vaccine cross reactivity

Publications (1)

Publication Number Publication Date
CN118338912A true CN118338912A (zh) 2024-07-12

Family

ID=86613140

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280079239.5A Pending CN118338912A (zh) 2021-11-30 2022-11-29 Nant covid疫苗交叉反应性

Country Status (8)

Country Link
US (4) US11911459B2 (https=)
EP (1) EP4440614A4 (https=)
JP (1) JP2024543954A (https=)
KR (1) KR20240113521A (https=)
CN (1) CN118338912A (https=)
AU (1) AU2022400924A1 (https=)
CA (1) CA3236215A1 (https=)
WO (1) WO2023102375A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7692925B2 (ja) * 2020-03-11 2025-06-16 ナントセル，インコーポレイテッド Ｃｏｖｉｄ－１９の治療及びその方法
EP4118225A1 (en) * 2020-03-13 2023-01-18 The Johns Hopkins University Exosomal nucleic acid vaccine modularly configured to harness multiple antigen presentation mechanisms
CN115666634A (zh) * 2020-03-27 2023-01-31 瑞典疫苗制药有限公司 用于治疗和预防冠状病毒的组合物和方法
WO2021255270A1 (en) * 2020-06-19 2021-12-23 Ziphius Vaccines Self-amplifying sars-cov-2 rna vaccine

Also Published As

Publication number Publication date
US12016916B2 (en) 2024-06-25
EP4440614A1 (en) 2024-10-09
JP2024543954A (ja) 2024-11-26
CA3236215A1 (en) 2023-06-08
US11911459B2 (en) 2024-02-27
KR20240113521A (ko) 2024-07-22
US20240424088A1 (en) 2024-12-26
WO2023102375A1 (en) 2023-06-08
US20230190921A1 (en) 2023-06-22
EP4440614A4 (en) 2025-12-17
US20240226282A1 (en) 2024-07-11
US12168052B2 (en) 2024-12-17
AU2022400924A1 (en) 2024-05-02
US20240108717A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
US11684668B2 (en) Replication-defective adenoviruses comprising nucleic acids encoding SARS-CoV-2 s glycoprotein and modified N protein comprising an endosomal targeting sequence
JP5165681B2 (ja) タンパク質断片又はペプチドカクテルとして送達される抗原を用いたワクチン接種によるサブドミナントエピトープを含むｔ細胞レパートリーの拡大
EA012037B1 (ru) Поливалентные вакцины, содержащие рекомбинантные вирусные векторы
EA016648B1 (ru) Применение дефектного по репликации рекомбинантного аденовируса, содержащего гетерологичную нуклеиновую кислоту, кодирующую антиген cs возбудителя малярии, и белкового антигена, содержащего белок cs или его фрагмент, для лечения или профилактики малярии
JP2003520597A (ja) 組換えフラビウイルスおよびその使用方法
US20230158137A1 (en) Coronavirus vaccine
Becker et al. Genetic immunization: bacteria as DNA vaccine delivery vehicles
CN115944722A (zh) 一种抗肿瘤mRNA疫苗及其制备方法和应用
WO2022105880A1 (zh) 融合基因及一种重组新型冠状病毒高效免疫dna疫苗及其构建方法和应用
Yu et al. Three types of human C p G motifs differentially modulate and augment immunogenicity of nonviral and viral replicon DNA vaccines as built‐in adjuvants
US12168052B2 (en) Nant COVID vaccine cross reactivity
CN110382518B (zh) 用于血清型a型口蹄疫病毒的嵌合疫苗
US20060263389A1 (en) Methods and compositions to enhance immune responses via recall antigens
JP2024505249A (ja) キメラアデノウイルスベクター
JP4535874B2 (ja) 肝炎に対するバクテリオファージを介する免疫
US12290558B2 (en) SARS-CoV-2 vaccines comprising human adenovirus vectors encoding spike and nucleocapsid-ETSD immunogens
US20260053900A1 (en) Use of virus-like particles in vaccination
US20250332246A1 (en) Enhanced expression via autotransporters
WO2024152845A1 (zh) 抗SARS-CoV-2或突变体mRNA疫苗和重组蛋白亚单位疫苗制备及应用
US20240239844A1 (en) Combinations of viral proteins, peptide sequences, epitopes, and methods and uses thereof
US20220023412A1 (en) Compositions Useful in Both Homologous And Heterologous Vaccine Regimens
Lee SARS-CoV-2 immunogenicity models inform novel strategies that can improve mRNA vaccines
Borah et al. Al-Shar'i NA, Dahabiyeh LA, Venugopala KN
CN121226564A (zh) 一种SARS-CoV-2刺突蛋白抗原表位混合多肽及其应用
EP4514386A1 (en) A bacteriophage-based, needle and adjuvant-free, mucosal covid-19 vaccine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination